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Treatment of leukemia relapse after allogeneic
hematopoietic stem cell transplantation by donor
lymphocyte infusion and STI-571
Donor lymphocyte infusion (DLI) has become standard 
therapy for relapse after allogeneic hematopoietic stem cell
transplantation (allo-HSCT).1-3 However, results in acute
leukemia are disappointing, probably because of the high pro-
liferative capacity of blast cells and the delayed anti-leukemic
effect of DLI. STI-571 is a tyrosine kinase inhibitor that has
substantial activity in Ph-chromosome-positive acute
leukemia. We present a patient illustrating that the associa-
tion of STI-571 (early reduction of the proportion of blasts)
and DLI (delayed anti-leukemic activity) may be useful. 
Donor lymphocyte infusion (DLI) has become standard thera-
py for relapse after allogeneic hematopoietic stem cell 
transplantation (HSCT).1-5 However, although DLI permits
achievement of complete remissions in the majority of cytoge-
netic or hematologic relapses of CML, results in more advanced
disease or in acute leukemia are disappointing, probably because
of the high proliferative capacity of blast cells1 and the delayed
anti-leukemic effect of DLI.6
STI-571 is a tyrosine kinase inhibitor that has substantial
activity in blast crises of CML and in Ph-chromosome-positive
acute leukemia.7 Since the outcome of DLI is better in early phase
CML than in more advanced relapse, a reduction in the propor-
tion of blasts in the marrow of patients with CML in blast crisis
or with Ph-chromosome-positive acute leukemia may be a 
useful step before DLI. This observation reports the first suc-
cessful use of STI-571 and DLI in a patient relapsing with Ph-
chromosome-positive acute leukemia after HSCT.
A 33-year old woman with biphenotypic Ph-chromosome-
positive acute leukemia in first relapse underwent an allogene-
ic CD34-selected (6.1×106 CD34+ cells) peripheral blood stem cell
transplant from an unrelated male donor after a conditioning
regimen consisting in 12 Gy total body irradiation, Ara-C (18
g/m2) and melphalan (140 mg/m2). She also received pre-emp-
tive DLI on day 0, 60 and 100 (with 1, 1 and 2×107 CD3+ cells
recovered from the CD34-negative fraction, respectively). Graft-
versus-host disease (GVHD) prophylaxis was carried out with
cyclosporine (CyA) plus short-course methotrexate. The post-
transplant course was unremarkable except for the occurrence
of grade III cutaneous acute GVHD that responded well to
steroids. 
Evaluation of response was carried out by cytology, standard
cytogenetics and fluorescent in situ hybridization (FISH) 
analysis and evaluation of bone marrow (BM) chimerism by FISH.
BM analysis on days 40 and 100 evidenced complete cytogenetic
remission (Figure 1) (although reverse transcription polymerase
chain reaction (RT-PCR) was still strongly positive) and a BM
chimerism of 98% and 99%, respectively. Unfortunately, the
patient relapsed on day 152 (0.2×109 blasts/L in blood and 75%
blasts in BM). Cytogenetics showed 100% Ph-chromosome-pos-
itive cells as well as a complex karyotype. Cyclosporine was dis-
continued and the patient received a large dose of donor lym-
phocytes (20×107 CD3+ cells). STI-571 therapy (600 mg/day) was
started on day 160 in the presence of 15.7×109 blasts/L in the
blood. Nine days later, blasts had disappeared from her blood.
Subsequently, the patient developed grade IV cutaneous acute
GVHD on day 172 that responded well to steroids and tacrolimus.
BM analysis on day 193 showed a complete response with a BM
chimerism of 99.8% and no BCR-ABL rearrangement on FISH
analysis (although RT-PCR remained slightly positive). A new
BM analysis on day 240 evidenced a complete molecular
response and the patient remains in CR for more than 150 days
after the onset of STI-571 therapy. STI-571 is being continued
without any side effects, except possibly the persistence of pre-
existing thrombocytopenia. 
Whereas responses to DLI are often delayed,1-4 the kinetics of
Figure 1. Evolution of blasts in peripheral blood as well as marrow leukemia and chimerism.
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response in our patient was similar to that reported by Druker7
in a patient with chronic myeloid leukemia in blast crisis receiv-
ing STI-571 alone, suggesting that the mechanism of blast clear-
ance in our patient was related to STI-571. However, less than
10% of patients with Ph-chromosome-positive acute leukemia
achieved complete cytogenetic response (and molecular respons-
es were not even reported) with STI-571 alone.7 In addition, less
than 15% of such patients treated with STI-571 remained in
hematologic remission after a follow-up of 58 to 349 days.7
Therefore, DLI with cyclosporine withdrawal most probably also
played an important role in the elimination of blast cells in our
patient who previously failed to benefit from much lower doses
of donor lymphocytes given under cyclosporine prophylaxis. On
the other hand, waiting for the probable relapse to occur before
administering donor lymphocytes would have 
substantially jeopardized the potential benefit of DLI.
We conclude that the combination of STI-571 and DLI may be
highly effective as treatment for Ph-chromosome-positive acute
leukemia relapsing after HSCT.8 Although we hope that reduc-
tion of tumor burden by STI-571 would enhance the efficacy of
DLI, longer follow-up is needed to see whether this strategy can
result in durable remission.
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